4-benzhydrylpyrazole | 150560-43-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-benzhydrylpyrazole
• 英文别名: 4-diphenylmethylpyrazole；4-benzhydryl-1H-pyrazole
• CAS: 150560-43-3
• 化学式: C₁₆H₁₄N₂
• 分子量: 234.301
• InChiKey: SSUIIXGMVCDOMM-UHFFFAOYSA-N

物化性质

• 沸点：
  401.3±14.0 °C(Predicted)
• 密度：
  1.147±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  28.7
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  4-benzhydrylpyrazole 在 sodium hydroxide 、 sodium hydride 作用下， 以 四氢呋喃 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 <2-(4-benzhydrylpyrazoyl)methyl-1,2,3,4-tetrahydro-5-naphthyloxy>acetic acid
  参考文献：
  名称：

  Nagao, Yuuki; Takahashi, Kanji; Torisu, Kazuhiko, Heterocycles, 1996, vol. 42, # 2, p. 517 - 523

  摘要：

  DOI：
• 作为产物：
  描述：

  3,3-二苯基丙醇 在 盐酸肼 、 potassium carbonate 、 对甲苯磺酸 、 三氯氧磷 作用下， 反应 2.0h， 生成 4-benzhydrylpyrazole
  参考文献：
  名称：

  Nagao, Yuuki; Takahashi, Kanji; Torisu, Kazuhiko, Heterocycles, 1996, vol. 42, # 2, p. 517 - 523

  摘要：

  DOI：

文献信息

• Pyrazol-1-yl phenoxyacetic acid compounds which have useful
  申请人：Ono Pharmaceutical Co., Ltd.

  公开号：US05378716A1

  公开（公告）日：1995-01-03

  We proposed a novel compound having an activity of PGI.sub.2 receptor agonist. A phenoxyacetic acid derivative of the formula ##STR1## A is --C(R.sup.1).dbd.N.about.OR.sup.2, --CH(R)NH--OR.sup.2, --COE, --SO.sub.2 E, --CH.sub.2 --NR.sup.3 --Y, --Z -- NR.sup.3 --CONR.sup.4 R.sup.5, --CH.sub.2 --OR.sup.6, --CO.sub.2 R.sup.6, --CH.sub.2 --O.about.N.dbd.CR.sup.7 R.sup.8, --CH.sub.2 --O--NHCHR.sup.7 R.sup.8, substituted by imidazolyl(methyl), pyrazolylmethyl, oxazolyl(methyl), thioxazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolylmethyl; T is alkylene, alkenylene, etc.; D is --CO.sub.2 R.sup.10, --CONR.sup.11 R.sup.12 ; E is (substitution) amino, hydradino; Y is substituted (thio) carbonyl, substituted sulfonyl; Z is --CH.dbd.N--, --CH.sub.2 NR.sup.3 --; R.sup.1, R.sup.3, R.sup.10 -R.sup.13 is each H or alkyl, etc.; R.sup.2, R.sup.4 -R.sup.9 is each H, alkyl or alkyl substituted by phenyl or hetero ring, etc. and non-toxic salts thereof, non-toxic acid addition salts thereof, possess an agonistic on PGI.sub.2 receptor, so it is useful for prevention and/or treatment of thrombosis, arteriosclosis, ischemic heart diseases, gastric ulcer and hypertention.

  我们提出了一种新型化合物，具有PGI.sub.2受体激动剂活性。该化合物是一种苯氧乙酸衍生物，化学式为##STR1##其中A为--C(R.sup.1).dbd.N.about.OR.sup.2, --CH(R)NH--OR.sup.2, --COE, --SO.sub.2 E, --CH.sub.2 --NR.sup.3 --Y, --Z -- NR.sup.3 --CONR.sup.4 R.sup.5, --CH.sub.2 --OR.sup.6, --CO.sub.2 R.sup.6, --CH.sub.2 --O.about.N.dbd.CR.sup.7 R.sup.8, --CH.sub.2 --O--NHCHR.sup.7 R.sup.8，通过咪唑基(甲基)、吡唑基甲基、噁唑基(甲基)、硫代噁唑基、异噁唑基、异硫代噁唑基、噁二唑基、三唑基甲基取代；T为烷基、烯烃基等；D为--CO.sub.2 R.sup.10, --CONR.sup.11 R.sup.12；E为(取代)氨基、氢氨基；Y为取代的(硫)羰基、取代的磺酰基；Z为--CH.dbd.N--, --CH.sub.2 NR.sup.3--；R.sup.1, R.sup.3, R.sup.10 -R.sup.13分别为H或烷基等；R.sup.2, R.sup.4 -R.sup.9分别为H、烷基或被苯基或杂环取代的烷基等，以及其非毒性盐、非毒性酸加盐，具有对PGI.sub.2受体的激动作用，因此对预防和/或治疗血栓形成、动脉硬化、缺血性心脏病、胃溃疡和高血压具有用处。
• [EN] PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO<br/>[FR] DÉRIVÉS D'ACIDE CARBONIQUE SUBSTITUÉS PAR PYRAZOLYLE EN TANT QUE MODULATEURS DU RÉCEPTEUR DE LA PROSTACYCLINE PGI2 ADAPTÉS AU TRAITEMENT DE TROUBLES LE FAISANT INTERVENIR
  申请人：ARENA PHARM INC

  公开号：WO2010068242A1

  公开（公告）日：2010-06-17

  Pyrazole derivatives of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (COPD).

  Formula Ia的吡唑衍生物及其药物组成物，可调节PGI2受体的活性。本发明的化合物和药物组成物用于治疗以下疾病：肺动脉高压（PAH）及相关疾病；血小板聚集；冠状动脉疾病；心肌梗死；短暂性缺血性发作；心绞痛；中风；缺血再灌注损伤；再狭窄；心房颤动；血栓形成在冠状动脉成形术或冠状动脉旁路手术个体中或在患有心房颤动的个体中；动脉粥样硬化；动脉粥样血栓形成；哮喘或其症状；糖尿病相关疾病，如糖尿病周围神经病变、糖尿病肾病或糖尿病视网膜病变；青光眼或其他眼睛异常眼压疾病；高血压；炎症；牛皮癣；银屑病性关节炎；类风湿性关节炎；克罗恩病；移植排斥；多发性硬化症；系统性红斑狼疮（SLE）；溃疡性结肠炎；缺血再灌注损伤；再狭窄；动脉粥样硬化；痤疮；1型糖尿病；2型糖尿病；败血症；慢性阻塞性肺疾病（COPD）。
• Fused benzeneoxyacetic acid derivatives
  申请人：Ono Pharmaceutical Co., Ltd.

  公开号：US05389666A1

  公开（公告）日：1995-02-14

  A fused benzeneoxyacetic acid derivative of the formula (I): ##STR1## R.sup.1 is OH, alkoxy, (alkyl)amino, residue of an amino acid; A is phenyl, alkyl substituted by phenyl, residue of an imidazole, imidazole-2-yloxy(thio), 2-oxoimidazole, pyrazole, oxadiazole, oxazole, triazole, isoxazole or isothiazole, in the group of benzene may be substituted by one to three of alkyl, alkoxy, halogen, nitro or trihalomethyl; e is 3-5; f is 1-3; p is 1-4; q is 0-2; r is 1-4; s is 0-3) and salts thereof possess an agonistic on PGI.sub.2 receptor, so it is useful for prevention and/or treatment of thrombosis, arteriosclerosis, inchemic heart diseases, gastric alcer and hypertention.

  一种公式（I）的融合苯氧基乙酸衍生物：##STR1## R.sup.1为OH、烷氧基、（烷基）氨基、氨基酸残基；A为苯基、被苯基取代的烷基、咪唑残基、咪唑-2-氧（硫）、2-氧代咪唑、吡唑、氧代二唑、氧唑、三唑、异氧唑或异硫唑，在苯环中可被1-3个烷基、烷氧基、卤素、硝基或三卤甲基取代；e为3-5；f为1-3；p为1-4；q为0-2；r为1-4；s为0-3）及其盐具有对PGI.sub.2受体的激动作用，因此对预防和/或治疗血栓形成、动脉粥样硬化、缺血性心脏病、胃溃疡和高血压有用。
• PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
  申请人：Tran Thuy-Anh

  公开号：US20110224262A1

  公开（公告）日：2011-09-15

  Pyrazole derivatives of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (COPD).

  公式Ia的吡唑衍生物及其制药组合物，用于调节PGI2受体的活性。本发明的化合物和制药组合物用于治疗以下疾病的有用方法：肺动脉高压（PAH）及相关疾病；血小板聚集；冠状动脉疾病；心肌梗死；短暂性脑缺血发作；心绞痛；中风；缺血再灌注损伤；再狭窄；房颤的血栓形成或在患有房颤的个体中的冠状动脉成形术或冠状动脉旁路手术；动脉粥样硬化；动脉粥样血栓形成；哮喘或其症状；与糖尿病相关的疾病，如糖尿病周围神经病、糖尿病肾病或糖尿病视网膜病变；青光眼或其他眼部异常眼压的疾病；高血压；炎症；牛皮癣；银屑病性关节炎；类风湿性关节炎；克罗恩病；移植排斥；多发性硬化症；系统性红斑狼疮（SLE）；溃疡性结肠炎；再灌注损伤；再狭窄；动脉粥样硬化；痤疮；1型糖尿病；2型糖尿病；败血症；慢性阻塞性肺疾病（COPD）。
• Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto
  申请人：Arena Pharmaceuticals, Inc.

  公开号：US10689372B2

  公开（公告）日：2020-06-23

  Pyrazole derivatives of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (COPD).

  可调节 PGI2 受体活性的式 Ia 吡唑衍生物及其药物组合物。本发明的化合物及其药物组合物适用于治疗下列疾病的方法肺动脉高压（PAH）及相关疾病；血小板聚集；冠状动脉疾病；心肌梗塞；短暂性脑缺血发作；心绞痛；中风；缺血再灌注损伤；再狭窄；心房颤动；血管成形术或冠状动脉搭桥术患者或心房颤动患者的血栓形成；动脉粥样硬化；动脉粥样血栓形成；哮喘或其症状；糖尿病相关疾病，如糖尿病周围神经病变、糖尿病肾病或糖尿病视网膜病变；青光眼或其他眼内压异常的眼部疾病；高血压；炎症；银屑病；银屑病关节炎；类风湿性关节炎；克罗恩病、移植排斥反应、多发性硬化症、系统性红斑狼疮 (SLE)、溃疡性结肠炎、缺血再灌注损伤、血管再狭窄、动脉粥样硬化、痤疮、1 型糖尿病、2 型糖尿病、败血症和慢性阻塞性肺病 (COPD)。